Impressive Financial Results for Q4 2024
Waldencast plc (NASDAQ: WALD), a pioneering beauty and wellness platform, has reported noteworthy financial outcomes for its fourth quarter of 2024. The company recorded net revenue of $72.1 million, demonstrating a robust comparable net revenue growth of 29.4% year-over-year. Adjusted EBITDA for the quarter reached $11.2 million, representing a doubling from the prior year.
The total net revenue for fiscal year 2024 stands at an impressive $273.9 million, which signifies a 27.5% growth in comparable net revenue. Adjusted EBITDA for the year hit $40.3 million, underscoring the company’s operational strength and market adaptability.
Brand Performance Highlights
Notably, Obagi Medical has positioned itself as the leading professional skincare brand within the U.S. for the year 2024. The brand’s remarkable success can be attributed to its emphasis on innovation and effective marketing strategies. Alongside this, Waldencast's Milk Makeup brand is expanding its reach, with an exciting launch planned for over 600 Ulta Beauty locations. This move is expected to further elevate brand visibility and access.
Michel Brousset, the company’s founder and CEO, expressed excitement about the trajectory of Waldencast, stating, "This transformative year showcased our capability to adapt and thrive in a dynamic market environment. As we continue to leverage the strengths of our brands, we are committed to enhancing operational efficiencies that support long-term growth and profitability.”
Detailed Q4 Financial Overview
The financial data illustrates a positive trend:
- Net Revenue: Increased by 30.8% to $72.1 million, attributed in part to Milk Makeup's channel expansion and Obagi Medical's growth in the Physician Dispense channel.
- Adjusted Gross Profit: Achieved $52.6 million, reflecting a gross margin of 73.0%, an improvement over previous year figures.
- Net Loss: Narrowed down from $32.7 million in Q4 2023 to $22.6 million in Q4 2024, indicating significant operational improvements.
- Liquidity: By the end of the quarter, Waldencast maintained cash equivalents of $14.8 million and net debt of $154.2 million, showcasing effective working capital management.
Strategic Adjustments and Future Outlook
Waldencast recently secured a new $205 million credit facility, designed to replace its previous arrangement, thereby bolstering its financial flexibility and extending debt maturities. This strategic maneuver will enable the company to better align its resources toward future growth initiatives.
The leadership anticipates that revenue growth will continue to accelerate in 2025, supported by an innovative product pipeline and a growing distribution network that includes the launching of Milk Makeup products at Ulta Beauty. The company aims to achieve mid-teens growth for net revenue and to further expand its adjusted EBITDA margin into the mid-to-high teens.
About Waldencast
Founded by Michel Brousset and Hind Sebti, Waldencast is dedicated to establishing a premier beauty and wellness operating platform by driving high-growth, purpose-driven brands. Its operational strategy aims at balancing robust brand identities while optimizing market responsiveness.
Frequently Asked Questions
What were Waldencast's Q4 2024 financial highlights?
Waldencast reported Q4 2024 net revenue of $72.1 million with an adjusted EBITDA of $11.2 million, showcasing significant growth compared to the previous year.
How did Obagi Medical perform in 2024?
Obagi Medical emerged as the fastest-growing skincare brand in the U.S. for 2024, fueled by effective marketing and product innovation.
What strategic moves has Waldencast made for future growth?
Waldencast secured a new $205 million credit facility to enhance flexibility and extend debt maturities, empowering future growth initiatives.
How did Milk Makeup contribute to Waldencast's growth?
Milk Makeup's expansion into over 600 Ulta Beauty locations in 2025 is expected to significantly enhance brand visibility and revenue.
What are Waldencast's expectations for 2025?
The company anticipates mid-teens net revenue growth and aims to improve adjusted EBITDA margin into the mid-to-high teens in the upcoming fiscal year.
